Journal
VACCINES
Volume 9, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9010004
Keywords
capripox; inactivated vaccine; LSDV; lumpy skin disease; vaccine; adjuvants
Categories
Funding
- Friedrich-Loeffler-Institut (Insel Riems, Germany)
- Zoetis (Olot, Spain) [Ri-0613]
Ask authors/readers for more resources
Capripox virus-induced diseases are considered serious threats to livestock animals and only live-attenuated vaccines are currently available for control. The development of effective inactivated vaccines against CaPV is challenging, but promising, as shown by recent studies on adjuvanted formulations inducing sterile immunity.
Capripox virus (CaPV)-induced diseases (lumpy skin disease, sheeppox, goatpox) are described as the most serious pox diseases of livestock animals, and therefore are listed as notifiable diseases under guidelines of the World Organisation for Animal Health (OIE). Until now, only live-attenuated vaccines are commercially available for the control of CaPV. Due to numerous potential problems after vaccination (e.g., loss of the disease-free status of the respective country, the possibility of vaccine virus shedding and transmission as well as the risk of recombination with field strains during natural outbreaks), the use of these vaccines must be considered carefully and is not recommended in CaPV-free countries. Therefore, innocuous and efficacious inactivated vaccines against CaPV would provide a great tool for control of these diseases. Unfortunately, most inactivated Capripox vaccines were reported as insufficient and protection seemed to be only short-lived. Nevertheless, a few studies dealing with inactivated vaccines against CaPV are published, giving evidence for good clinical protection against CaPV-infections. In our studies, a low molecular weight copolymer-adjuvanted vaccine formulation was able to induce sterile immunity in the respective animals after severe challenge infection. Our findings strongly support the possibility of useful inactivated vaccines against CaPV-infections, and indicate a marked impact of the chosen adjuvant for the level of protection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available